Fred Sanger developed technologies that won him two Nobel Prizes and revolutionized biological research. Yet, in spite of this record, the question has been raised as to whether, in the current scientific climate, he might be unsuccessful in obtaining a grant because of a productivity that would be viewed as too limited. In imagining how a National Institutes of Health study section today might treat a proposal from Sanger to sequence DNA, we can ask whether there are lessons from his career that suggest changes to the grant review process.
- Copyright © 2014 by the Genetics Society of America
Available freely online through the author-supported open access option.